BI 3923948 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=60 | Suspended | Sponsor: Boehringer Ingelheim | Recruiting ➔ Suspended

Monotherapy • Trial suspension • Oncology • Solid Tumor

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Oncology • Solid Tumor

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Boehringer Ingelheim

Monotherapy • Trial initiation date • Oncology • Solid Tumor

1538-0001: A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors) (clinicaltrialsregister.eu) - P1 | N=35 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

New P1 trial • Oncology • Solid Tumor